Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis

BACKGROUND: Dipeptidyl peptidase 4 (DPP-4) inhibitors are newer oral anti-diabetic agents which have been approved by the Food and Drug Administration for the treatment of patients with type 2 diabetes mellitus (T2DM). In this analysis, we aimed to systematically compare the cardiovascular outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Dan, Jin, Biao, Chen, Wei, Yun, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399924/
https://www.ncbi.nlm.nih.gov/pubmed/30832701
http://dx.doi.org/10.1186/s40360-019-0293-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399924/
https://www.ncbi.nlm.nih.gov/pubmed/30832701
http://dx.doi.org/10.1186/s40360-019-0293-y

Ejemplares similares